The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.

Saved in:
Bibliographic Details
Title: The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6.
Authors: Wang H; Eli Lilly and Company, Indianapolis, IN, USA., Nery ESM; Eli Lilly and Company, Indianapolis, IN, USA., Ardayfio P; Eli Lilly and Company, Indianapolis, IN, USA., Khanna R; Eli Lilly and Company, Indianapolis, IN, USA., Svaldi DO; Eli Lilly and Company, Indianapolis, IN, USA., Shcherbinin S; Eli Lilly and Company, Indianapolis, IN, USA., Xu W; Eli Lilly and Company, Indianapolis, IN, USA., Andersen SW; Eli Lilly and Company, Indianapolis, IN, USA., Hauck PM; Eli Lilly and Company, Indianapolis, IN, USA., Brooks DA; Eli Lilly and Company, Indianapolis, IN, USA., Collins EC; Eli Lilly and Company, Indianapolis, IN, USA., Salloway S; Butler Hospital, and Department of Neurology and Department of Psychiatry, Warren Alpert Medical School of Brown University, Providence, RI, USA., Mintun MA; Eli Lilly and Company, Indianapolis, IN, USA., Sims JR; Eli Lilly and Company, Indianapolis, IN, USA. Electronic address: sims_john_r@lilly.com.
Source: The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2025 Sep; Vol. 12 (8), pp. 100266. Date of Electronic Publication: 2025 Jul 05.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study
Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101638820 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2426-0266 (Electronic) Linking ISSN: 22745807 NLM ISO Abbreviation: J Prev Alzheimers Dis Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2426-0266
DOI:10.1016/j.tjpad.2025.100266